louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03933033: Erbium-YAG Laser Versus Platelet Rich Plasma in the Treatment of Atrophic Acne Scars
Official title: Fractional Erbium-YAG Laser Versus Platelet Rich Plasma in the Treatment of Atrophic Acne Scars: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acne Vulgaris
Scars
Keywords: Acne scars
Erbium-YAG laser
platelet-rich plasma
Lead sponsor: Aswan University Hospital
Sponsor class: OTHER
Collaborators: name: South Valley University
First posted: 2019-05-01
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aim to assess the efficacy of Er-YAG laser 2940nm and PRP as a single line of treatment in comparison with combined treatment in atrophic post acne scars.


Eligibility criteria: Inclusion Criteria:

* patients with atrophic post acne scars classified on the basis of Goodman and Baron's Qualitative classification, no active acne lesions and patients with atrophic scars only

Exclusion Criteria:

* patients with positive history of keloidal tendency, positive history of bleeding tendency, platelet disorder, patients with any acute infection on face like, herpes, folliculitis, patients with HIV, HBsAg, patients with a history of autoimmune diseases or patients on immunosuppressive drugs.

Primary outcomes:
measure: Change in grade of acne scares according toQualitative scarring grading system of Goodman and Baron
timeFrame: 6 months
measure: Change in clinical appearance of acne scare accordinga four-point scale for assessment of clinical improvement of skin smoothness
timeFrame: 6 month
measure: Change in patient satisfaction usinga four-point scale; Grade 4 highly satisfied, Grade 3 satisfied, Grade 2 neutral and Grade 1 dissatisfied
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Aswan
country: Egypt
facility: Aswan University Hospital
Study officials:
References:
citation: El-Taieb MA, Ibrahim HM, Hegazy EM, Ibrahim AK, Gamal AM, Nada EA. Fractional Erbium-YAG Laser and Platelet-Rich Plasma as Single or Combined Treatment for Atrophic Acne Scars: A Randomized Clinical Trial. Dermatol Ther (Heidelb). 2019 Dec;9(4):707-717. doi: 10.1007/s13555-019-00318-1. Epub 2019 Aug 16.
Clinical trial NCT04848233: Using CGM for Evaluating Effects of Food on Glucose Regulation in Healthy Humans
Official title: Development of Methodology for Use of Continuous Blood Glucose Measurements When Evaluating Meal Effects on Glucose Regulation - a Pilot Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glycemic Control
Diet, Food and Nutrition
Lead sponsor: DoubleGood AB
Sponsor class: INDUSTRY
Collaborators: name: starScience GmbH
First posted: 2021-04-19
Enrollment: 6
Sex: ALL
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The specific goal of this pilot study is to evaluate if it is possible to detect a statistical difference in postprandial glycemia after meals served with and without a drink previously shown to reduce postprandial glycemia by about 25%. A third drink, with a new recipe, is also included for comparisons. Six participants will carry continuous blood glucose monitors for 10 days and follow a specific meal schedule. The data from this study will form the basis for forming hypothesis of future studies as well as make appropriate calculations of statistical power.


Eligibility criteria: Inclusion Criteria:

* BMI 25-29.9 kg/m\^2
* HOMA-IR \< 2.5
* Fasting glucose \< 6.1 mmol/L
* Stable weight since 3 months
* Access to iPhone with Bluetooth 4.0 and iOS 13 or later

Exclusion Criteria:

* Diabetes
* Pharmacological treatment known to interfer with metabolism
* Antibiotics treatment the latest 3 months
* Vegetarian/Vegan diet
* Use of tobacco
* Pregnancy or breast-feeding

Primary outcomes:
measure: Postprandial glucose response
timeFrame: From start of meal (0 min) to 120 min postprandially
Secondary outcomes:
measure: Glycemic variability
timeFrame: 24 hour cycles
Other outcomes:
Locations:
city: Lund
country: Sweden
facility: Aventure AB
Study officials:
affiliation: Aventure AB
name: Elin Ostman, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Samigullin A, Humpert PM, Ostman E. Continuous glucose monitoring as a close to real life alternative to meal studies - a pilot study with a functional drink containing amino acids and chromium. Front Med Technol. 2022 Aug 18;4:931837. doi: 10.3389/fmedt.2022.931837. eCollection 2022.
Clinical trial NCT01543633: EEG Studies of Induction and Recovery From Propofol Induced General Anesthesia
Official title: Electroencephalogram Studies of Induction and Recovery From Propofol Induced General Anesthesia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Brain Activity Under Sedation
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2012-03-05
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 36
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to investigate how the commonly used anesthetic drug propofol works in the brain to produce loss of consciousness. While under general anesthesia your brain waves will be measured using electroencephalogram (EEG). On a separate day, the patient's brain will be imaged using magnetic resonance imaging (MRI).


Eligibility criteria: Inclusion Criteria:

* Healthy, non-smoking male and female volunteers, ages 18-36 with normal body weight.
* American Society of Anesthesiologists (ASA) physical status I

Exclusion Criteria:

* History of head trauma
* Surgical aneurysm clips
* Cardiac pacemaker
* Prosthetic heart valve
* Neurostimulator
* Implanted pumps
* Cochlear implants
* Metal rods, plates
* Screws
* Intrauterine device
* Hearing aid
* Dentures (which might create NMR artifacts)
* Metal injury to eyes

Primary outcomes:
measure: EEG Power in Alpha, Slow, and Delta Bands
timeFrame: 11 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Emery N Brown, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00742833: A Phase II Study of KUC-7483 in Patients With Overactive Bladder
Official title: A Randomized, Double Blind, Placebo Controlled, Phase II Study of KUC-7483 in Patients With Overactive Bladder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Overactive Bladder (OAB)
Keywords: Overactive bladder
Frequency
Micturition
Urgency
Urge urinary incontinence
β3-agonist
Lead sponsor: Kissei Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2008-08-28
Enrollment: 400
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To investigate the efficacy and safety of KUC-7483 in overactive bladder patients.


Eligibility criteria: Inclusion Criteria:

* Patients with a symptom of overactive bladder for more than 6 months.
* Patients who meet the following condition during the 3-day bladder diary period.

  * the mean number of micturitions per 24 hours is ≥8 times
  * the mean number of urgency episodes per 24 hours is ≥1 time

Exclusion Criteria:

* Patients who are diagnosed as stress urinary incontinence are predominant.
* Patients with urinary calculus, interstitial cystitis, or clinically significant urinary tract infection.

Primary outcomes:
measure: Change from baseline in mean number of micturitions per 24 hours
timeFrame: 12 weeks
Secondary outcomes:
measure: Change from baseline in mean number of urgency episodes per 24 hours
timeFrame: 12 weeks
measure: Change from baseline in mean number of incontinence episodes per 24 hours
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Hokkaido region
country: Japan
facility: Japan
city: Kansai region
country: Japan
facility: Japan
city: Kanto region
country: Japan
facility: Japan
city: Kyushu region
country: Japan
facility: Japan
city: Shikoku region
country: Japan
facility: Japan
city: Tohoku region
country: Japan
facility: Japan
Study officials:
affiliation: Kissei Pharmaceutical Co., Ltd.
name: Yasuhiro Omori
role: STUDY_DIRECTOR
References:
Clinical trial NCT05659433: Contrast-enhanced vs. B-mode Ultrasound-guided Percutaneous Biopsy of Retroperitoneal Tumors
Official title: Contrast-enhanced vs. B-mode Ultrasound-guided Percutaneous Biopsy of Retroperitoneal Tumors - a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Retroperitoneal Neoplasms
Keywords: Percutaneous biopsy
Contrast-enhanced ultrasonography
CEUS
Retroperitoneal neoplasms
Lead sponsor: Iuliu Hatieganu University of Medicine and Pharmacy
Sponsor class: OTHER
Collaborators: name: Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
First posted: 2022-12-21
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Background: Retroperitoneal tumors are typically large and inhomogeneous, with a variable amount of necrosis within the tumor mass which decreases the diagnostic yield of biopsy (false negative or inadequate).

Rationale: Real-time contrast enhancement can highlight the viable tumoral tissue and avoid the necrotic area.

Aims: To compare contrast-enhanced ultrasound (CEUS) guidance and conventional (B-mode) ultrasound (US) guidance in terms of diagnostic yield, need for repeat biopsy, and rate of adverse events.

Methods: A consecutive series of patients with previously documented retroperitoneal tumors and indications for percutaneous biopsy were randomly assigned to benefit from the standard of practice B-mode US-guided biopsy or CEUS-guided biopsy.

The diagnostic accuracy, need for repeat biopsy, and adverse events were noted.


Eligibility criteria: Inclusion Criteria:

* All patients with retroperitoneal tumors with indication for percutaneous biopsy

Exclusion Criteria:

* Tumors inaccessible for ultrasound guided biopsy
* Standard contraindications for biopsy (altered coagulation tests, poor performance status)
* Lack of written informed consent

Primary outcomes:
measure: Number of patients with a biopsy sample adequate for pathology interpretation
timeFrame: 4 weeks
Secondary outcomes:
measure: Number of patients requiring a second biopsy due to prior inadequate sampling
timeFrame: 6 weeks
measure: Number of patients with procedural-related adverse events
timeFrame: One week
Other outcomes:
Locations:
city: Cluj-Napoca
country: Romania
facility: Prof. Dr. O. Fodor Regional Institute of Gastroenterology and Hepatology
state: Cluj County
Study officials:
affiliation: Prof. Dr. O. Fodor Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca
name: Zeno Spârchez, MD, Prof.
role: STUDY_CHAIR
References:
Clinical trial NCT00476333: The Effect of Custom-Made Biomechanical Perturbation Platform on Kinetics, Kinematics and Electromyography in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Healthy
Keywords: EMG
Kinetics
Kinematics
Perturbation
Footwear
Lead sponsor: Assaf-Harofeh Medical Center
Sponsor class: OTHER_GOV
First posted: 2007-05-22
Sex: MALE
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Introduction: Kinetic, kinematic and electromyographic activity of the lower limb have been shown to be influenced by various footwear-generated biomechanical manipulations (e.g. soles. Insoles, orthoses). A novel biomechanical device comprising four modular elements attached onto foot-worn platforms was recently developed. Each element can be individually calibrated (Position, convexity, height and resilience) to induce a specific biomechanical challenge.

Objectives: The aim of this study is to evaluate the influence of specific biomechanical challenges on Kinetics, kinematics and electromyographic activity of the lower limb.

Design: Prospective, case control Setting: Motion analyses will be conducted during level walking with (1) a three-dimensional motion analysis system and (2) ground reaction force analysis using force platforms (3) Electro-Myography system. Each subject will be examined in 16 different settings of the biomechanical system


Eligibility criteria: Inclusion Criteria:

* Healthy
* Similar anthorpometric profile (i.e. weight, shoe size, height, dominant leg)

Exclusion Criteria:

* Previous orthopedic, musculosceletal or neurological pathology

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Technion Israel institute of technology, Biomechanical and bio-robotics division gait laboratory
Study officials:
affiliation: Asaf-Harofeh Medical Center
name: Nahum Halperin, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02657733: Comparison Study Between Nellcor Respiration Rate Technology (RRoxi) and Masimo Acoustic Respiration Rate (RRa)
Official title: Comparison Study Between Nellcor Respiration Rate Technology (RRoxi) and Masimo Acoustic Respiration Rate (RRa)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Healthy
Keywords: Respiratory Conditions for Adults
Lead sponsor: Medtronic - MITG
Sponsor class: INDUSTRY
Collaborators: name: Herzog Hospital
First posted: 2016-01-18
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Respiration rate is a critical vital sign that provides early detection of respiratory compromise and patient distress. Continuous monitoring of respiration rate is performed in patients under different clinical conditions, including post-surgery or different respiratory diseases. Clinician observation, pulse oximetry, and capnography are used individually or in combination to monitor ventilation during sedation and on post-surgical patients. The American Society of Anesthesiologists mandates the monitoring of respiration by measuring end tidal carbon dioxide (RRetco2) during procedural sedation and anesthesia. Other techniques for respiration rate measurement include different technologies such as acoustic respiratory rate (RRa). The aim of this study is to compare the accuracy of RRetco2 and RRa under certain respiratory conditions.


Eligibility criteria: Inclusion Criteria:

* Without Clinical diagnosis of chronic obstructive pulmonary disease (COPD)
* Without Clinical diagnosis of heart disease.

Exclusion Criteria:

* Want to be excluded
* Breathing difficulties
* Unabling or unwilling to follow the protocol.
* Contact allergy to the adhesive neck sensor.

Primary outcomes:
measure: The influence of different breathing rates (normal breathing, tachypnea, and bradypnea) on the accuracy of respiratory rate in breaths per minute as measured by the tested devices compared to a reference device.
timeFrame: 6 hours
Secondary outcomes:
measure: The influence of hearing or performing noises on the accuracy of respiratory rates (in breaths per minute) as measured by the tested devices compared to a reference device.
timeFrame: 6 months
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Herzog Hospital
Study officials:
affiliation: Herzog Hospital
name: Michal Eisenberg, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00099333: Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents
Official title: An Exploratory Study of the Safety of Substituting Exenatide for Insulin in Patients With Type 2 Diabetes Who Have Been Using Insulin in Combination With Oral Antidiabetic Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Type 2 Diabetes Mellitus
Keywords: exenatide
exendin-4
Amylin
Eli Lilly
diabetes
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
Collaborators: name: Eli Lilly and Company
First posted: 2004-12-13
Enrollment: 49
Sex: ALL
Minimum age (years): 35
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will look at the safety of substituting exenatide for insulin in patients with type 2 diabetes who are currently taking insulin and oral antidiabetic agent(s).

Detailed description: This is an exploratory, multicenter, open-label, 2-arm, parallel trial. Approximately 30 patients with type 2 diabetes, currently on a sulfonylurea, or meglitinide and/or metformin and insulin therapy, will be randomized to discontinue insulin and substitute it with exenatide or remain on their current diabetes therapy regimen. All patients will continue their current diet and exercise regimen during the study.

Eligibility criteria: Inclusion Criteria:

* Patients have been treated with insulin for \>=3 months up to 12 years.
* HbA1c \<=10.5%.
* Body mass index (BMI) between 27 kg/m2 and 40 kg/m2.

Exclusion Criteria:

* Patients previously received exenatide or GLP-1 analogs.
* Patients have been treated for greater than 2 weeks with thiazolidinediones or alpha-glucosidase inhibitors within 3 months prior to screening.

Primary outcomes:
measure: Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 16
timeFrame: Baseline, Week 16
Secondary outcomes:
Other outcomes:
Locations:
city: Chula Vista
country: United States
facility: Research Site
state: California
city: Butte
country: United States
facility: Research Site
state: Montana
city: Portland
country: United States
facility: Research Site
state: Oregon
city: Nashville
country: United States
facility: Research Site
state: Tennessee
city: San Antonio
country: United States
facility: Research Site
state: Texas
Study officials:
affiliation: Eli Lilly and Company
name: James Malone, MD
role: STUDY_DIRECTOR
References:
citation: Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, Kinninger LA, Trautmann ME. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012 Jun;14(6):546-54. doi: 10.1111/j.1463-1326.2012.01561.x. Epub 2012 Feb 10.
citation: Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care. 2007 Nov;30(11):2767-72. doi: 10.2337/dc06-2532. Epub 2007 Jun 26.
Clinical trial NCT01425333: The Impact of Surgical Treatment of Endometriomas on Ovarian Reserve
Official title: The Impact of Surgical Treatment of Ovarian Endometriomas on Ovarian Reserve: a Randomised Controlled Trial of Laparoscopic Ovarian Cystectomy Versus Cyst Ablation - a Pilot Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Endometriosis
Keywords: Ovarian endometriomas
Laparoscopy
Cystectomy
Ablation
Lead sponsor: University Hospitals of Derby and Burton NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: University Hospitals of Derby and Burton NHS Foundation Trust
First posted: 2011-08-30
Enrollment: 20
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to assess which of two commonly used surgical procedures in the treatment of ovarian cysts called endometriomas (cutting out of the cyst - "cystectomy", or draining it and cauterising it's inner lining - "ablation") causes the least damage to the ovary and is therefore best at maintaining the future fertility potential of a patient.


Eligibility criteria: Inclusion Criteria:

* Women undergoing laparoscopic surgery for treatment of unilateral endometriomas measuring ≥ 3cm and ≤ 8cm in diameter

Exclusion Criteria:

* Patients who have received oestrogen suppressing drugs (e.g. oral contraceptive pills, GnRHa) during the previous six months
* Patients who have previously undergone surgical treatment of endometriomas
* Patients with bilateral endometriomas
* Patients with endometriomas of less than 3cm in size or more than 8cm in size
* Pre-surgical evidence of reduced ovarian reserve
* Pregnant patients
* Patients unable to give informed consent e.g. patients with mental incapacity

Primary outcomes:
measure: Anti-Mullerian Hormone (AMH)
timeFrame: 6 months post-operatively
Secondary outcomes:
measure: Follicle Stimulating Hormone (FSH)
timeFrame: 6 months
measure: Antral Follicle Count (AFC)
timeFrame: 3 months
Other outcomes:
Locations:
city: Derby
country: United Kingdom
facility: Royal Derby Hospital
Study officials:
affiliation: University of Nottingham and Derby Hospitals NHS foundation Trust
name: Saad Amer, MD, MRCOG
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05682833: Adjunctive Use Of A Novel Hyaluronic Acid/Chlorhexidine Gel In The Non Surgical Treatment Of Periodontitis
Official title: Adjunctive Use Of A Novel Hyaluronic Acid/Chlorhexidine Gel In The Non Surgical Treatment Of Periodontitis: A Split Mouth Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Periodontitis
Hyaluronic Acid
Chlorhexidine
Lead sponsor: University of Sharjah
Sponsor class: OTHER
First posted: 2023-01-12
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Split mouth RCT
Primary purpose: TREATMENT

Brief summary: General Objective :

To evaluate the outcome of non surgical periodontal therapy with local drug delivery adjunct to scaling and root planning

Specific Objective :

To determine the effect of intra-pocket application of hyaluronic acid /chlorohexidine gel in non surgical periodontal treatment on clinical periodontal parameters and microbiological level .


Eligibility criteria: Inclusion Criteria:

* Age : 20-60 years old
* At least 20 remaining teeth
* Periodontitis stage III and IV ,Grade A, B and C

Exclusion Criteria:

* Patients taking specific medications: antibiotic , anticoagulants or anti-inflammatory
* Previous periodontal therapy in the past 3-6 months.
* Immunocompromised patients
* Systemically diseased patients: Diabetes ,osteoporosis etc
* History of allergies or hypersensitivity reactions to chlorohexidine or Hyaluronic acid
* Pregnant or lactating women.
* Heavy Smokers (more than 20/day)

Primary outcomes:
measure: pocket depth
timeFrame: 2 months
measure: Bleeding on Probing
timeFrame: 2 months
measure: Clinical attachment level
timeFrame: 2 months
Secondary outcomes:
measure: Plaque index
timeFrame: 2 months
Other outcomes:
Locations:
city: Sharjah
country: United Arab Emirates
facility: University Dental Hospital Sharjah
Study officials:
affiliation: University of Sharjah
name: Zahi BADRAN, Phd
role: STUDY_DIRECTOR
References: